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Objectives: Data on antibiotic consumption in the community were collected from 30 EU/EEA countries over
two decades. This article reviews temporal trends, seasonal variation, presence of change-points and changes in
the composition of the main antibiotic groups.
Methods: For the period 1997–2017, data on consumption of antibiotics, i.e. antibacterials for systemic use
(ATC group J01), in the community, aggregated at the level of the active substance, were collected using
the WHO ATC/DDD methodology (ATC/DDD index 2019). Consumption was expressed in DDD per 1000
inhabitants per day and in packages per 1000 inhabitants per day. Antibiotic consumption was analysed
based on ATC-3 groups, and presented as trends, seasonal variation, presence of change-points and
compositional changes.
Results: In 2017, antibiotic consumption in the community expressed in DDD per 1000 inhabitants per day var-
ied by a factor 3.6 between countries with the highest (Greece) and the lowest (the Netherlands) consumption.
Antibiotic consumption in the EU/EEA did not change significantly over time. Antibiotic consumption showed a
significant seasonal variation, which decreased over time. The number of DDD per package significantly
increased over time. The proportional consumption of sulphonamides and trimethoprim (J01E) relative to other
groups significantly decreased over time, while the proportional consumption of other antibacterials (J01X)
relative to other groups significantly increased over time.
Conclusions: Overall, antibiotic consumption in the community in the EU/EEA did not change during 1997–2017,
while seasonal variation consistently decreased over time. The number of DDD per package increased during
1997–2017.
Introduction
Over time, misuse of antibiotics has led to antimicrobial resistance,
resulting in treatment failure, increased costs of care and elevated
mortality. In order to fight this global problem, comparable and re-
liable information of antibiotic consumption is essential.1 This art-
icle presents data from the European Surveillance of Antimicrobial
Consumption Network (ESAC-Net2, formerly ESAC) on antibiotic
consumption in the community (i.e. primary care sector) for 30 EU/
EEA countries in 1997–2017. It updates previous ESAC studies
published in 2006 and 2011.3,4 The objective of this study was to
analyse temporal trends, seasonal variation and the presence of
change-points in antibiotic consumption in the community for the
period 1997–2017, as well as to analyse the composition of anti-
biotic consumption over time.
Methods
The methods for collecting and analysing the data are described in the
introductory article of this series.5 In summary, data on consumption of
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antibiotics, i.e. antibacterials for systemic use (ATC group J01) aggregated
at the level of the active substance, were collected using the WHO ATC/DDD
methodology (ATC/DDD index 20196) and expressed in DDD per 1000
inhabitants per day. In addition, where data were available, antibiotic
consumption was also expressed in packages per 1000 inhabitants per day.
Antibiotics were classified in 10 ATC groups: b-lactam antibacterials,
penicillins (J01C), other b-lactam antibacterials (J01D), macrolides, lincosa-
mides and streptogramins (J01F), quinolone antibacterials (J01M), tetracy-
clines (J01A), sulphonamides and trimethoprim (J01E), other antibacterials
(J01X), amphenicols (J01B), aminoglycoside antibacterials (J01G) and
combinations of antibacterials (J01R). Due to limited consumption of the
last three groups, these were combined and their consumption was pre-
sented as ‘other antibiotics’.
The evolution of the number of DDD per package over time was
assessed using a linear mixed model. The temporal trend, seasonal vari-
ation and presence of change-points in antibiotic consumption were
assessed using a non-linear change-point mixed model fitted to quarterly
data expressed in DDD per 1000 inhabitants per day from 1997 to 2017.7
The relative proportions of the main groups were assessed through a com-
positional data analysis modelling yearly data expressed in DDD per 1000
inhabitants per day from 1997 to 2017.8
Results
An overview of consumption of antibacterials for systemic use
(ATC J01) in the community, expressed in DDD and packages per
1000 inhabitants per day for all participating countries between
1997 and 2017 is available as Supplementary data at JAC Online
(Tables S1 and S2, respectively).
Antibiotic consumption in the community in 2017
The proportion of antibiotics (ATC J01) represented by the main
ATC-3 groups is presented in Table 1. Figure 1 shows the consump-
tion of antibiotics in the community, expressed in DDD per 1000
inhabitants per day, for 30 EU/EEA countries in 2017. Antibiotic
consumption varied by a factor of 3.6 between countries with the
highest (32.15 DDD per 1000 inhabitants per day in Greece) and
the lowest (8.94 DDD per 1000 inhabitants per day in the
Netherlands) consumption in 2017.
The most frequently consumed antibiotics in the community in
2017 were the b-lactam antibacterials, penicillins (J01C), with
proportional consumption (out of total consumption) ranging
from 27.88% (Poland) to 66.39% (Denmark). The proportional
consumption ranged from 0.22% in Denmark to 23.96% in Greece
for other b-lactam antibacterials (J01D), from 4.77% in Sweden to
26.29% in Luxembourg for macrolides, lincosamides and streptog-
ramins (J01F), from 2.46% in Norway to 21.49% in Cyprus (total
care data, i.e. community and hospital sector combined) for quin-
olone antibacterials (J01M), from 2.51% in Italy to 28.22% in the
United Kingdom for tetracyclines (J01A), from 0.07% in Lithuania
to 7.55% in Finland for sulphonamides and trimethoprim (J01E),
from 0.17% in Ireland (nitrofurantoin (J01XE01) consumption not
included) to 27.46% in Norway for other antibacterials (J01X), and
from 0.01% in Portugal to 1.51% in Malta for other antibiotics
(J01B, J01G and J01R combined).
Figure 2 shows consumption of antibiotics (J01) in the commu-
nity expressed in packages per 1000 inhabitants per day for 20 EU/
EEA countries in 2017. Based on packages rather than DDD, Greece
also showed the highest consumption (5.42 packages per 1000
inhabitants per day) while Sweden showed the lowest consump-
tion (0.95 packages per 1000 inhabitants per day). The ranking of
countries for their consumption expressed in DDD per 1000 inhabi-
tants per day or in packages per 1000 inhabitants per day was
similar (Table 2). The lowest mean number of DDD per package
was observed for France and Italy (both 4.7 DDD per package) and
the highest for Sweden (11.8 DDD per package). In the EU/EEA, the
number of DDD per package significantly increased over time dur-
ing 1997–2017, with the steepness of this increase significantly
reducing over the time period.
Longitudinal data analysis, 1997–2017
The best fit was obtained for a model including two change-points:
one in the first quarter of 2004 and another in the last quarter
of 2008. The final model fits the observed data well (Figure S1).
The longitudinal data analysis estimated an average antibiotic
consumption (ATC J01) in the EU/EEA of 18.046 (SE 1.410) DDD per
1000 inhabitants per day in 1997, which did not change signifi-
cantly over time: #0.017 (SE 0.022) DDD per 1000 inhabitants per
day per quarter between 1997 and the first quarter of 2004;
!0.037 (SE 0.041) DDD per 1000 inhabitants per day per quarter
between the second quarter of 2004 and the last quarter of 2008;
and #0.014 (SE 0.059) DDD per 1000 inhabitants per day per quar-
ter afterwards. In addition, the analysis showed significant sea-
sonal variation with an amplitude of 3.808 (SE 0.342) DDD per
1000 inhabitants per day, which decreased significantly over time:
#0.012 (SE 0.002) DDD per 1000 inhabitants per day per quarter
(Figure 3).
Based on the final fitted model, antibiotic consumption in the
community in 1997 was significantly above average in Belgium,
Greece and Slovakia, and significantly below average in Austria,
Denmark, Estonia, Germany, the Netherlands, Sweden and the
United Kingdom (observed profiles shown in Figures S2 and S3).
The seasonal variation was significantly larger than average in
Belgium, Greece, Hungary, Italy, Luxembourg and Slovakia, and
significantly smaller than average in Denmark, Estonia, Finland,
Iceland, Ireland, the Netherlands, Slovenia, Sweden and the
United Kingdom. The decrease in antibiotic consumption be-
tween 1997 and the first quarter of 2004 was significantly larger
than average in Belgium and Spain. The increase in antibiotic
consumption between the second quarter of 2004 and the
last quarter of 2008 was significantly larger than average in
Table 1. Distribution of antibiotic consumption (ATC J01) in the commu-
nity by ATC level-3, EU/EEA, 2017
Group (ATC code) Proportion (%)
Tetracyclines (J01A) 11.28
Amphenicols (J01B) 0.03
b-Lactam antibacterials, penicillins (J01C) 42.30
Other b-lactam antibacterials (J01D) 11.62
Sulphonamides and trimethoprim (J01E) 2.85
Macrolides, lincosamides and streptogramins (J01F) 16.10
Aminoglycoside antibacterials (J01G) 0.17
Quinolone antibacterials (J01M) 9.47
Combinations of antibacterials (J01R) 0.11
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Belgium, Denmark and Lithuania. There were no countries
showing a significantly larger than average decrease from the
first quarter of 2009 onwards.
Compositional data analysis, 1997–2017
The proportional consumption of sulphonamides and trimetho-
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Figure 1. Consumption of antibiotics (ATC J01) in the community, expressed in DDD (ATC/DDD index 2019) per 1000 inhabitants per day, 30 EU/EEA
countries, 2017. For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania, total care data, i.e. community and hos-
pital sector combined, are used. For Ireland, nitrofurantoin (J01XE01) consumption is not included. For Slovenia, sulphonamide and trimethoprim
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Figure 2. Consumption of antibiotics (ATC J01) in the community, expressed in packages per 1000 inhabitants per day, 20 EU/EEA countries, 2017.
For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Ireland, nitrofurantoin (J01XE01) consumption is not included.
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consumption of all other groups (Table 3). The proportional con-
sumption of other antibacterials (J01X) significantly increased over
time relative to that of all other groups, except for the other antibi-
otics (J01B, J01G and J01R combined). In addition, the proportion-
al consumption of b-lactam antibacterials (J01C) significantly
increased over time relative to that of tetracyclines (J01A) and
significantly decreased over time relative to that of quinolone
antibacterials (J01M). The proportional consumption of tetracy-
clines (J01A) significantly decreased over time relative to that of
macrolides, lincosamides and streptogramins (J01F), quinolone
antibacterials (J01M) and other antibiotics (J01B, J01G and J01R
combined). The proportional consumption of other b-lactam anti-
bacterials (J01D) significantly decreased relative that of quinolone
antibacterials (J01M). The proportional consumption of macro-
lides, lincosamides and streptogramins (J01F) significantly
decreased relative to that of quinolone antibacterials (J01M).
Trends of proportional consumption of antibiotic groups in
individual countries are shown in Figure S4. When comparing the
composition of the consumption of antibiotics (ATC J01) in 2017
with that in 2009, the proportion of sulphonamides and trimetho-
prim (J01E) decreased in most of the participating EU/EEA coun-
tries, with the largest decreases observed for Slovenia (#8.92%),
Latvia (#5.32%) and Iceland (#5.17%). However, increases were
also observed, with the largest increases reported for Slovakia
(!3.54%; 2016 data), Romania (!1.94%; total care data, i.e. com-
munity and hospital sector combined) and Italy (!1.49%).
The proportion of other antibacterials (J01X) increased in most
countries, with the largest increases observed for Poland
(!11.00%) and Norway (!8.29%). Decreases were also observed,
with the largest decreases reported for Lithuania (#8.24%) and
Finland (#1.51%). The proportion of b-lactam antibacterials (J01C)
increased in most countries, with the largest increases observed
for France (!11.91%), Portugal (!10.14%) and Croatia (!9.34%).
Decreases were also observed, with the largest decreases
observed for Poland (#7.84%), Bulgaria (#7.78%) and
Luxembourg (#5.72%). The proportions of tetracyclines (J01A),
quinolone antibacterials (J01M), macrolides, lincosamides and
streptogramins (J01F) and other b-lactam antibacterials (J01D)
increased for some countries while they decreased for others.
More detailed results for the main antibiotic groups are presented
in separate articles in this series.9–13
Discussion
We demonstrated that EU/EEA antibiotic consumption in the com-
munity expressed in DDD per 1000 inhabitants per day did not
change significantly during 1997–2017. In an international study
analysing the trend of total (i.e. covering both community and hos-
pital sector) antibiotic consumption in 76 countries expressed in
DDD per 1000 inhabitants per day, consumption remained stable
among high-income countries between 2000 and 2015. Given
that the majority of the EU/EEA countries belong to the high-in-
come category, this is consistent with the results of our study.14
The analyses also revealed seasonality of antibiotic consump-
tion in the community, which was observed for all EU/EEA coun-
tries and decreased significantly over time. This may result in a
reduction in the incidence of Clostridioides (Clostridium) difficile
infections as predicted by mathematical modelling.15 While a
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seasonality in bacterial pathogens, the extent of the observed
seasonality suggests inappropriate prescribing for viral (mostly
respiratory) infections during the winter season.16,17 In addition,
conclusions should not be drawn based on a single quality indica-
tor. In a separate article in this series, we evaluated 13 quality
indicators, thus allowing for more-solid conclusions.18
We explored countries’ ranking based on antibiotic consumption
expressed in DDD per 1000 inhabitants per day or in packages per
1000 inhabitants per day, and found these to be similar. However,
since the average number of DDD per package significantly
increased between 1997 and 2017, this finding is time-dependent.
Both metrics can be used to summarize a country’s overall antibiotic
consumption. In countries solely dispensing complete packages, a
package may be considered as a surrogate for a prescription (and
hence one treated patient), although some patients may only need
half a package while others may need two or more packages.
However, in countries where pharmacies dispense the exact
number of singe units to fulfil a prescription, e.g. the Netherlands
and the UK, the number of packages is not a suitable metric and the
number of prescriptions instead of the number of packages should
be monitored. The DDD is a technical unit defined as the assumed
average maintenance dose per day for the main indication of a
substance in adults. For antibiotics, the DDD is based on the treat-
ment of infections of moderate severity. Its standardization and
updates to take into account changes in prescribing practices
make the DDD an international standard for surveillance of con-
sumption of medicinal products, including antibiotics.19
Nevertheless, the DDD is not a suitable metric for children since
the DDD are defined for adults, and specific indicators have been
defined for antibiotic consumption in children.20 Because our aim
in this series was to provide an in-depth overview—in compos-
ition and over time—of antibiotic consumption, we used the
most complete data, i.e. data expressed in DDD per 1000 inhabi-
tants per day, for further analyses.
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Figure 3. Estimated trend (solid line) and linear trend (dashed line) of consumption of antibiotics (ATC J01) in the community based on quarterly
data, 25 EU/EEA countries, 1997–2017. b0, predicted consumption in the first quarter of 1997; b1, predicted increase (if positive)/decrease (if negative)
in consumption per quarter; b2, predicted difference in slope after versus before the first change-point; b3, predicted difference in slope after versus
before the second change-point; b4, predicted difference in slope after versus before the third change-point; b0
S, predicted amplitude of the upward
winter and downward summer peak in consumption; b1
S, predicted increase (if positive)/decrease (if negative) of the amplitude of the upward winter
and downward summer peak in consumption per quarter; d, shift in timing of the upward winter and downward summer peak from one year to an-
other. *Statistically significant at significance level 0.05.
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The inter-country variability in consumption of antibiotics
(ATC J01) expressed in DDD per 1000 inhabitants per day was
substantial. This has also been reported for European countries
that are not part of the ESAC-Net, but covered by the WHO Europe
Antimicrobial Medicines Consumption Network in which consump-
tion varied by a factor of 4.3, from 36.4 DDD per 1000 inhabitants
per day in Turkey to 8.5 in Azerbaijan.21
Despite changes in DDD values in 2019, which mostly
affected the b-lactam antibacterials, penicillins (J01C), this
group remained the most consumed antibiotic group in all 30
EU/EEA countries (Czechia 2015 data, Slovakia 2016 data). This
finding confirms that of previously published studies.1,2 While
the proportional consumption of sulphonamides and trimetho-
prim (J01E) decreased in most countries, the proportional con-
sumption of other antibacterials (J01X) increased in most
countries. Given that total antibiotic consumption did not
change significantly over time between 1997 and 2017, this
implies that consumption of antibiotics from one subgroup was
merely replaced by consumption of antibiotics from another
subgroup, rather than being reduced overall. More detailed dis-
cussions on the main antibiotic groups are given in separate
articles in this series.9–13
To further broaden our understanding of appropriate
prescribing and the variations between and within EU/EEA
countries over time, more detailed data on antibiotic use (e.g.
linked to patient records containing age, gender, indication for
prescribing and comorbidities) and antimicrobial resistance
rates, and information on treatment guidelines at the national
level would be needed.
Nevertheless, the data on antibiotic consumption in the com-
munity in EU/EEA countries, available from ESAC-Net, together
with the tools of compositional and longitudinal data analyses
provided in this series may enable countries to evaluate their own
antibiotic consumption by linking their country-specific change-
points to possible explanations, e.g. targeted surveillance initia-
tives or the implementation of national guidelines. In addition, it
allows countries to evaluate the impact of public awareness cam-
paigns and important policy changes for a more prudent use of
antibiotics in the community.22
While this study has a major strength in the number of partici-
pating countries and the completeness of their recorded data, it
has a major limitation in the aggregated nature of the collected
data. Because the data only contained information on countries’
antibiotic consumption rates, we were unable to distil any findings
by age (e.g. children or elderly) or gender. In addition, the aggrega-
tion prevents a distinction between high-but-appropriate and in-
appropriate antibiotic prescribing, which is deemed quintessential
in fighting overconsumption of antibiotics. For a discussion on the
limitations of the statistical approach used in this study and
potential explanations for the common change-points detected
through these analyses, we refer to the tutorial paper in this
series.7
In conclusion, while antibiotic consumption did not change sig-
nificantly during 1997–2017, seasonal variation decreased.
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